Relationship Between Gut Microbiome, Probiotics, and Mild Cognitive Impairment

Mild Cognitive Impairment (MCI) Clinical Trial

Official title: Relationship Between Gut Microbiome, Probiotics, and Mild Cognitive Impairment

Status Recruiting

Clinical Trial Summary

This study is to evaluate whether the consumption of probiotics can improve the symptoms of patients with mild cognitive impairment; also evaluate the effects of probiotics on patients' blood, oxidation and stress related indicators.

Clinical Trial Description

Mild cognitive impairment (MCI) is the stage between the expected cognitive decline of normal aging and the more serious decline of dementia. It can involve problems with memory, language, thinking and judgment that are greater than normal age-related changes. Probiotics are regarded as active microorganisms. When consumed in sufficient amounts, participants can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body, and may produce host health, including delaying disease and regulating metabolic disease progression and prevent complications. ;

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Mild Cognitive Impairment (MCI)

• NCT number: NCT04971096
• Study type: Interventional
• Source: Mackay Memorial Hospital
• Contact: Shu-I Wu, MD, PhD
• Phone: +886 975835215
• Email: shuiwu@g.ntu.edu.tw
• Status: Recruiting
• Phase: N/A
• Start date: April 1, 2022
• Completion date: February 24, 2024